Trajectories of antidepressant drugs during pregnancy: A cohort study from a community-based sample.
EGB database
antidepressant
postpartum
pregnancy
prescription
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
22
01
2020
revised:
30
05
2020
accepted:
11
06
2020
pubmed:
6
8
2020
medline:
27
7
2021
entrez:
6
8
2020
Statut:
ppublish
Résumé
The aim of this study was to monitor the trajectories of antidepressant use during pregnancy and the postpartum period among women chronically treated with antidepressants before their pregnancy, and to assess characteristics associated with each trajectory. This cohort study included all pregnant women whose data were included in the General Sample of Beneficiaries (EGB) database affiliated with the French Health Insurance System, from 2009 to 2014. Women were followed up until 6 months after childbirth. Chronic treatment was defined as exposure over the 6-month period preceding pregnancy. A group-based trajectory model (GBMT) was estimated to identify distinctive longitudinal profiles of antidepressant use. Among 760 women chronically treated with antidepressants before their pregnancy, 55.8% stopped their treatment permanently in the first trimester, 20.4% discontinued it for a minimum of 3 months and resumed it postpartum, and 23.8% maintained it throughout pregnancy and postpartum. No sociodemographic or medical characteristics were associated with any trajectory group. Women who maintained treatment presented more frequent obstetric complications and postpartum psychiatric disorders. Among women who interrupted treatment, prescription of benzodiazepines and anxiolytics decreased initially but rose postpartum to a higher level than before pregnancy. Pregnant women treated with antidepressant require a re-evaluation of psychiatric treatment. It is necessary to pay attention to obstetric complications for severely depressed women. Additionally, as relapse was associated with increased benzodiazepine use, it is important to carefully monitor all women who stop antidepressant treatment during pregnancy.
Substances chimiques
Antidepressive Agents
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
965-987Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Hurault-Delarue C, Lacroix I, Bénard-Laribière A, Montastruc J-L, Pariente A, Damase-Michel C. Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort. Eur Arch Psychiatry Clin Neurosci. 2019;269(7):841-849. https://doi.org/10.1007/s00406-018-0906-2
Haute Autorité de Santé. Épisode dépressif caractérisé de l'adulte: prise en charge en soins de premier recours-Synthèse de la recommandation de bonne pratique. 2017.
Sundström Poromaa I, Comasco E, Georgakis MK, Skalkidou A. Sex differences in depression during pregnancy and the postpartum period. J Neurosci Res. 2017;95(1-2):719-730. https://doi.org/10.1002/jnr.23859
Chatillon O, Even C. La dépression de l'antepartum: prévalence, diagnostic, traitement. Encéphale. 2010;36(6):443-451. https://doi.org/10.1016/j.encep.2010.02.004
Lefkovics E, Baji I, Rigó J. Impact of maternal depression on pregnancies and on early attachment. Infant Ment Health J. 2014;35(4):354-365. https://doi.org/10.1002/imhj.21450
Andersson L, Sundström-Poromaa I, Wulff M, Aström M, Bixo M. Implications of antenatal depression and anxiety for obstetric outcome. Scribd. 2004;104(3):467-476.
Freeman M. Psychotropic medication use during pregnancy. J Clin Psychiatry. 2015;76(7):990-991.
Howard LM, Flach C, Mehay A, Sharp D, Tylee A. The prevalence of suicidal ideation identified by the Edinburgh postnatal depression scale in postpartum women in primary care: findings from the RESPOND trial. BMC Pregnancy Childbirth. 2011;11:57. https://doi.org/10.1186/1471-2393-11-57
Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. 2005;8(2):77-87. https://doi.org/10.1007/s00737-005-0080-1
Soufia M, Aoun J, Gorsane M-A, Krebs M-O. ISRS et grossesse: revue de la littérature. Encéphale. 2010;36(6):513-516. https://doi.org/10.1016/j.encep.2010.02.003
Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67(10):1012-1024. https://doi.org/10.1001/archgenpsychiatry.2010.111
Freyer AM. Drugs in pregnancy and lactation 8th edition: a reference guide to fetal and neonatal risk. Obstet Med. 2009;2(2):89. https://doi.org/10.1258/om.2009.090002 (Book review)
Jansson LM, Velez M. Neonatal abstinence syndrome. Curr Opin Pediatr. 2012;24(2):252-258. https://doi.org/10.1097/MOP.0b013e32834fdc3a
Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry. 2002;159(10):1667-1673. https://doi.org/10.1176/appi.ajp.159.10.1667
Misri S, Kostaras D. The use of selective serotonin reuptake inhibitors in pregnancy and lactation: a review. J Soc Obstet Gynaecol Can. 1999;21(2):120-123.
Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 1995;15(6):417-420.
Ram D, Gandotra S. Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. Indian J Psychiatry. 2015;57(Suppl 2):S354-S371. https://doi.org/10.4103/0019-5545.161504
Dragioti E, Solmi M, Favaro A, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiat. 2019;76(12):1241-1255. https://doi.org/10.1001/jamapsychiatry.2019.2859
ANSM: Agence nationale de sécurité du médicament et des produits de santé. Traitement par antidépresseurs. https://www.ansm.sante.fr/Dossiers/Traitements-par-antidepresseurs/Traitement-par-antidepresseurs/(offset)/0. Accessed June 11, 2019.
Molyneaux E, Telesia LA, Henshaw C, Boath E, Bradley E, Howard LM. Antidepressants for preventing postnatal depression. Cochrane Database Syst Rev. 2018;(4):CD004363. https://doi.org/10.1002/14651858.CD004363.pub3
Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5):499-507. https://doi.org/10.1001/jama.295.5.499
Yazici E, Kirkan TS, Aslan PA, Aydın N, Yazici AB. Untreated depression in the first trimester of pregnancy leads to postpartum depression: high rates from a natural follow-up study. Neuropsychiatr Dis Treat. 2015;11:405-411. https://doi.org/10.2147/NDT.S77194
Hurault-Delarue C, Chouquet C, Savy N, et al. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? New method to study drug exposure during pregnancy. Pharmacoepidemiol Drug Saf. 2016;25(7):770-777. https://doi.org/10.1002/pds.4000
Hurault-Delarue C, Chouquet C, Savy N, et al. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics: evaluation of outcomes after in utero drug exposure. Pharmacoepidemiol Drug Saf. 2017;26(5):561-569. https://doi.org/10.1002/pds.4199
Bais B, Molenaar NM, Bijma HH, et al. Prevalence of benzodiazepines and benzodiazepine-related drugs exposure before, during and after pregnancy: a systematic review and meta-analysis. J Affect Disord. 2020;269:18-27. https://doi.org/10.1016/j.jad.2020.03.014
Einarson A. Challenges for healthcare providers in treating women with psychiatric disorders during pregnancy. J Popul Ther Clin Pharmacol J Ther Popul Pharamcologie Clin. 2012;19(3):e371-e375.
Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry. 1997;58(Suppl 7):31-35. discussion, 36
Reminick A, Cohen S, Einarson A. Managing depression during pregnancy. Womens Health (Lond Engl). 2013;9(6):527-535. https://doi.org/10.2217/whe.13.58
Jimenez-Solem E, Andersen JT, Petersen M, et al. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS ONE. 2013;8(4):e63034. https://doi.org/10.1371/journal.pone.0063034
Ramos E, Oraichi D, Rey E, Blais L, Bérard A. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG. 2007;114(9):1055-1064. https://doi.org/10.1111/j.1471-0528.2007.01387.x
Liu X, Musliner KL, Agerbo E, et al. Treatment indications for antidepressants prescribed to pregnant women: a population-based descriptive study from Denmark. Pharmacoepidemiol Drug Saf. 2020;29(3):347-351. https://doi.org/10.1002/pds.4953
Bandoli G, Kuo GM, Sugathan R, Chambers CD, Rolland M, Palmsten K. Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period. Arch Womens Ment Health. 2018;21(4):411-419. https://doi.org/10.1007/s00737-018-0809-2
Martin-Latry K, Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19(3):256-265. https://doi.org/10.1002/pds.1912
Nagin DS. Analyzing developmental trajectories: a semiparametric, group-based approach. Psychol Methods. 1999;4(2):139-157. https://doi.org/10.1037/1082-989X.4.2.139
Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J Clin Pharmacol. 2019;85:1260-1269. https://doi.org/10.1111/bcp.13892
Massoullié G, Chouki C, Mulliez A, et al. Effect of optimization of medical treatment on long-term survival of patients with heart failure after implantable cardioverter defibrillator and cardiac resynchronization device implantation (from the French national EGB database). Am J Cardiol. 2018;121(6):725-730. https://doi.org/10.1016/j.amjcard.2017.12.013
MacMillan KK, Lewis AJ, Watson SJ, Galbally M. Maternal depression and the emotional availability of mothers at six months postpartum: findings from the Mercy Pregnancy and Emotional Wellbeing Study (MPEWS) pregnancy cohort. J Affect Disord. 2020;266:678-685. https://doi.org/10.1016/j.jad.2020.01.109
Grimm K, Stegmann G. Modeling change trajectories with count and zero-inflated outcomes: challenges and recommendations. Addict Behav. 2019;94:4-15.
Marascuilo LA, McSweeney M. Nonparametric post hoc comparisons for trend. Psychol Bull. 1967;67(6):401-412. https://doi.org/10.1037/h0020421
Bernard N, Forest J-C, Tarabulsy GM, Bujold E, Bouvier D, Giguère Y. Use of antidepressants and anxiolytics in early pregnancy and the risk of preeclampsia and gestational hypertension: a prospective study. BMC Pregnancy Childbirth. 2019;19(1):146. https://doi.org/10.1186/s12884-019-2285-8
Jiang H-Y, Xu L-L, Li Y-C, Deng M, Peng C-T, Ruan B. Antidepressant use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis. J Psychiatr Res. 2016;83:160-167. https://doi.org/10.1016/j.jpsychires.2016.09.001
Médicaments psychotropes: consommations et pharmacodépendances. Inserm - La science pour la santé. https://www.inserm.fr/information-en-sante/expertises-collectives/medicaments-psychotropes-consommations-et-pharmacodependances. Accessed May 2, 2019.
Ververs T, Kaasenbrood H, Visser G, Schobben F, de Jong-van den Berg L, Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol. 2006;62(10):863-870. https://doi.org/10.1007/s00228-006-0177-0
Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. 2019;80(4):18r12412. https://doi.org/10.4088/JCP.18r12412
WHO. Adherence to long-term therapies: evidence for action [Internet]. http://www.who.int/chp/knowledge/publications/adherence_report/en/. Accessed December 19, 2019.